Maria Sala

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7160053/publications.pdf Version: 2024-02-01



Μαρία δαι α

#	Article	IF	CITATIONS
1	Use of health services among long-term breast cancer survivors in Spain: longitudinal study based on real-world data. Journal of Cancer Survivorship, 2022, 16, 132-141.	2.9	1
2	Mammographic features of benign breast lesions and risk of subsequent breast cancer in women attending breast cancer screening. European Radiology, 2022, 32, 621-629.	4.5	9
3	Influence of surgical technique on complications, readmissions and clinical progress of breast cancer in women participating in screening programs. Revista De Senologia Y Patologia Mamaria, 2022, 35, 33-41.	0.1	0
4	Long-Term Risk of Breast Cancer after Diagnosis of Benign Breast Disease by Screening Mammography. International Journal of Environmental Research and Public Health, 2022, 19, 2625.	2.6	7
5	Adherence of long-term breast cancer survivors to follow-up care guidelines: a study based on real-world data from the SURBCAN cohort. Breast Cancer Research and Treatment, 2022, 193, 455-465.	2.5	3
6	Impact of Detection Mode in a Large Cohort of Women Taking Part in a Breast Screening Program. The Journal of Breast Health, 2022, 18, 182-189.	1.0	2
7	Cost-effectiveness Analysis of Peripherally Inserted Central Catheters Versus Central Venous Catheters for in-Hospital Parenteral Nutrition. Journal of Patient Safety, 2022, 18, e1109-e1115.	1.7	2
8	Factors that Influence Treatment Delay for Patients with Breast Cancer. Annals of Surgical Oncology, 2021, 28, 3714-3721.	1.5	13
9	Breast density, benign breast disease, and risk of breast cancer over time. European Radiology, 2021, 31, 4839-4847.	4.5	19
10	Developing and validating an individualized breast cancer risk prediction model for women attending breast cancer screening. PLoS ONE, 2021, 16, e0248930.	2.5	7
11	Effect of an information leaflet on breast cancer screening participation: A cluster randomized controlled trial. BMC Public Health, 2021, 21, 1301.	2.9	3
12	Multimorbidity clusters among longâ€ŧerm breast cancer survivors in Spain: Results of the <scp>SURBCAN</scp> study. International Journal of Cancer, 2021, 149, 1755-1767.	5.1	10
13	Differences in breast cancer risk after benign breast disease by type of screening diagnosis. Breast, 2020, 54, 343-348.	2.2	12
14	Use of real-world data to study health services utilisation and comorbidities in long-term breast cancer survivors (the SURBCAN study): study protocol for a longitudinal population-based cohort study. BMJ Open, 2020, 10, e040253.	1.9	7
15	Readmissions and complications in breast ductal carcinoma in situ: A retrospective study comparing screen- and non-screen-detected patients. Women's Health, 2020, 16, 174550652096589.	1.5	0
16	Comorbidities and Mortality in Patients With COVID-19 Aged 60 Years and Older in a University Hospital in Spain. Archivos De Bronconeumologia, 2020, 56, 756-758.	0.8	21
17	Impact of adjuvant chemotherapy on the survival of patients with breast cancer diagnosed by screening. Cancer Medicine, 2019, 8, 6662-6670.	2.8	3
18	Diagnostic Accuracy of CYFRA21-1 in the Differential Diagnosis of Pleural Effusions. Anticancer Research, 2019, 39, 5071-5076.	1.1	2

#	Article	IF	CITATIONS
19	Changes in mammographic density over time and the risk of breast cancer: An observational cohort study. Breast, 2019, 46, 108-115.	2.2	14
20	A systematic review and quality assessment of individualised breast cancer risk prediction models. British Journal of Cancer, 2019, 121, 76-85.	6.4	89
21	Effect of information about the benefits and harms of mammography on women's decision making: The InforMa randomised controlled trial. PLoS ONE, 2019, 14, e0214057.	2.5	36
22	Health care services use among long-term breast cancer survivors: a systematic review. Journal of Cancer Survivorship, 2019, 13, 477-493.	2.9	13
23	Exploring the Role of Breast Density on Cancer Prognosis among Women Attending Population-Based Screening Programmes. Journal of Oncology, 2019, 2019, 1-8.	1.3	2
24	Factors associated with readmissions in women participating in screening programs and treated for breast cancer: a retrospective cohort study. BMC Health Services Research, 2019, 19, 940.	2.2	3
25	Personalized breast cancer screening strategies: A systematic review and quality assessment. PLoS ONE, 2019, 14, e0226352.	2.5	38
26	Changes in FIT values below the threshold of positivity and short-term risk of advanced colorectal neoplasia: Results from a population-based cancer screening program. European Journal of Cancer, 2019, 107, 53-59.	2.8	21
27	External validation of the PREDICT tool in Spanish women with breast cancer participating in populationâ€based screening programmes. Journal of Evaluation in Clinical Practice, 2019, 25, 873-880.	1.8	3
28	Mammographic breast density: How it affects performance indicators in screening programmes?. European Journal of Radiology, 2019, 110, 81-87.	2.6	29
29	Variabilidad en la práctica de la cirugÃa mamaria en mujeres participantes en el programa de cribado poblacional de cáncer de mama. CirugÃa Española, 2019, 97, 89-96.	0.2	4
30	Dissemination of health technologies: Trends in the use of diagnostic test in breast cancer screening. Journal of Healthcare Quality Research, 2019, 34, 177-184.	0.6	0
31	Clinical and histologic characteristics of breast cancers in women with previous pathologic diagnosis of benign breast disease in Spain. Breast Journal, 2018, 24, 509-518.	1.0	1
32	Survival and Disease-Free Survival by Breast Density and Phenotype in Interval Breast Cancers. Cancer Epidemiology Biomarkers and Prevention, 2018, 27, 908-916.	2.5	9
33	Anxiety and depression in women with breast cancer: Social and clinical determinants and influence of the social network and social support (DAMA cohort). Cancer Epidemiology, 2018, 55, 123-129.	1.9	52
34	Health services research in patients with breast cancer (CAMISS-prospective): study protocol for an observational prospective study. BMC Cancer, 2018, 18, 54.	2.6	9
35	A qualitative study on a decision aid for breast cancer screening: Views from women and health professionals. European Journal of Cancer Care, 2017, 26, e12660.	1.5	21
36	Cumulative risk of breast cancer screening outcomes according to the presence of previous benign breast disease and family history of breast cancer: supporting personalised screening. British Journal of Cancer, 2017, 116, 1480-1485.	6.4	13

#	Article	IF	CITATIONS
37	Biomarkers expression in benign breast diseases and risk of subsequent breast cancer: a case–control study. Cancer Medicine, 2017, 6, 1482-1489.	2.8	13
38	Impact of comorbidity on survival by tumour location: Breast, colorectal and lung cancer (2000–2014). Cancer Epidemiology, 2017, 49, 66-74.	1.9	32
39	Incremental cost of nosocomial bacteremia according to the focus of infection and antibiotic sensitivity of the causative microorganism in a university hospital. Medicine (United States), 2017, 96, e6645.	1.0	9
40	Evaluation of two strategies for the interpretation of tumour markers in pleural effusions. Respiratory Research, 2017, 18, 103.	3.6	16
41	Association between socioeconomic deprivation and colorectal cancer screening outcomes: Low uptake rates among the most and least deprived people. PLoS ONE, 2017, 12, e0179864.	2.5	24
42	The effect of information about the benefits and harms of mammography on women's decision-making: study protocol for a randomized controlled trial. Trials, 2017, 18, 426.	1.6	9
43	Influence of Social Determinants, Lifestyle, Emotional Well-Being and the Use of Unconventional Therapies in Breast Cancer Progression in a Cohort of Women in Barcelona: Protocol for the DAMA Cohort. JMIR Research Protocols, 2017, 6, e249.	1.0	7
44	Prevalence of persistent pain after breast cancer treatment by detection mode among participants in population-based screening programs. BMC Cancer, 2016, 16, 735.	2.6	14
45	Eleven-year descriptive analysis of closed court verdicts on medical errors in Spain and Massachusetts. BMJ Open, 2016, 6, e011644.	1.9	11
46	Association of diabetes and diabetes treatment with incidence of breast cancer. Acta Diabetologica, 2016, 53, 99-107.	2.5	30
47	A retrospective review of medical errors adjudicated in court between 2002 and 2012 in Spain. International Journal for Quality in Health Care, 2016, 28, 33-39.	1.8	17
48	Risk of Breast Cancer in Women with False-Positive Results according to Mammographic Features. Radiology, 2016, 280, 379-386.	7.3	33
49	Impact of age- and gender-specific cut-off values for the fecal immunochemical test for hemoglobin in colorectal cancer screening. Digestive and Liver Disease, 2016, 48, 542-551.	0.9	23
50	Cross-national comparison of screening mammography accuracy measures in U.S., Norway, and Spain. European Radiology, 2016, 26, 2520-2528.	4.5	47
51	Cost Attributable to Nosocomial Bacteremia. Analysis According to Microorganism and Antimicrobial Sensitivity in a University Hospital in Barcelona. PLoS ONE, 2016, 11, e0153076.	2.5	32
52	Mammographic and clinical characteristics of different phenotypes of screen-detected and interval breast cancers in a nationwide screening program. Breast Cancer Research and Treatment, 2015, 154, 403-415.	2.5	36
53	The effect of smoking on prostate cancer survival. European Journal of Cancer Prevention, 2015, 24, 335-339.	1.3	13
54	Clinical utility of determining tumor markers in patients with signs and symptoms of cancer. Clinical Chemistry and Laboratory Medicine, 2015, 53, 485-91.	2.3	11

#	Article	IF	CITATIONS
55	Does digital mammography suppose an advance in early diagnosis? Trends in performance indicators 6Âyears after digitalization. European Radiology, 2015, 25, 850-859.	4.5	17
56	Breast cancer risk after diagnosis by screening mammography of nonproliferative or proliferative benign breast disease: a study from a population-based screening program. Breast Cancer Research and Treatment, 2015, 149, 237-244.	2.5	57
57	Cost-Effectiveness and Harm-Benefit Analyses of Risk-Based Screening Strategies for Breast Cancer. PLoS ONE, 2014, 9, e86858.	2.5	113
58	Budget Impact Analysis of Switching to Digital Mammography in a Population-Based Breast Cancer Screening Program: A Discrete Event Simulation Model. PLoS ONE, 2014, 9, e97459.	2.5	24
59	Impact of Risk Factors on Different Interval Cancer Subtypes in a Population-Based Breast Cancer Screening Programme. PLoS ONE, 2014, 9, e110207.	2.5	24
60	Rate of Detection of Advanced Neoplasms in Proximal Colon by Simulated Sigmoidoscopy vs Fecal Immunochemical Tests. Clinical Gastroenterology and Hepatology, 2014, 12, 1708-1716.e4.	4.4	13
61	Investigación en cribado de cáncer de mama: camino hacia estrategias personalizadas y decisiones compartidas. Revista De Senologia Y Patologia Mamaria, 2014, 27, 176-182.	0.1	3
62	Gene Expression Profiling in True Interval Breast Cancer Reveals Overactivation of the mTOR Signaling Pathway. Cancer Epidemiology Biomarkers and Prevention, 2014, 23, 288-299.	2.5	10
63	Evaluation of the interval cancer rate and its determinants on the Girona health region's early breast cancer detection program. BMC Cancer, 2014, 14, 558.	2.6	10
64	Tumor phenotype and breast density in distinct categories of interval cancer: results of population-based mammography screening in Spain. Breast Cancer Research, 2014, 16, R3.	5.0	60
65	Cumulative risk of cancer detection in breast cancer screening by protocol strategy. Breast Cancer Research and Treatment, 2013, 138, 869-877.	2.5	6
66	Breast cancer detection risk in screening mammography after a false-positive result. Cancer Epidemiology, 2013, 37, 85-90.	1.9	24
67	Clinical and radiological features of breast tumors according to history of false-positive results in mammography screening. Cancer Epidemiology, 2013, 37, 660-665.	1.9	4
68	Can the Gail model increase the predictive value of a positive mammogram in a European population screening setting? Results from a Spanish cohort. Breast, 2013, 22, 83-88.	2.2	7
69	Aggressiveness features and outcomes of true interval cancers. European Journal of Cancer Prevention, 2013, 22, 21-28.	1.3	39
70	Seventeen-years overview of breast cancer inside and outside screening in Denmark. Acta Oncológica, 2013, 52, 48-56.	1.8	16
71	Trends in Detection of Invasive Cancer and Ductal Carcinoma In Situ at Biennial Screening Mammography in Spain: A Retrospective Cohort Study. PLoS ONE, 2013, 8, e83121.	2.5	9
72	Inter- and intraradiologist variability in the BI-RADS assessment and breast density categories for screening mammograms. British Journal of Radiology, 2012, 85, 1465-1470.	2.2	124

#	Article	IF	CITATIONS
73	Effect of protocol-related variables and women's characteristics on the cumulative false-positive risk in breast cancer screening. Annals of Oncology, 2012, 23, 104-111.	1.2	42
74	Effect of false-positive results on reattendance at breast cancer screening programmes in Spain. European Journal of Public Health, 2012, 22, 404-408.	0.3	27
75	A prognostic score based on clinical factors and biomarkers for advanced non-small cell lung cancer. International Journal of Biological Markers, 2012, 27, 257-262.	1.8	16
76	The Psychological Impact of a False-Positive Screening Mammogram in Barcelona. Journal of Cancer Education, 2012, 27, 780-785.	1.3	7
77	Detection methods predict differences in biology and survival in breast cancer patients. BMC Cancer, 2012, 12, 604.	2.6	20
78	Hospital costs of nosocomial multi-drug resistant Pseudomonas aeruginosa acquisition. BMC Health Services Research, 2012, 12, 122.	2.2	113
79	Determination of the biological variation of S100Î ² and lactate dehydrogenase in disease-free patients with malignant melanoma. Clinical Chemistry and Laboratory Medicine, 2012, 50, 927-9.	2.3	5
80	Prevalence of faecal incontinence and analysis of its impact on quality of life and mental health. Colorectal Disease, 2011, 13, 899-905.	1.4	45
81	Effect of start age of breast cancer screening mammography on the risk of false-positive results. Preventive Medicine, 2011, 53, 76-81.	3.4	23
82	Cost-effectiveness of early detection of breast cancer in Catalonia (Spain). BMC Cancer, 2011, 11, 192.	2.6	29
83	Differences in radiological patterns, tumour characteristics and diagnostic precision between digital mammography and screen-film mammography in four breast cancer screening programmes in Spain. European Radiology, 2011, 21, 2020-2028.	4.5	32
84	Effect of false-positives and women's characteristics on long-term adherence to breast cancer screening. Breast Cancer Research and Treatment, 2011, 130, 543-552.	2.5	42
85	Descriptive analysis of childbirth healthcare costs in an area with high levels of immigration in Spain. BMC Health Services Research, 2011, 11, 77.	2.2	7
86	Reduction in False-Positive Results after Introduction of Digital Mammography: Analysis from Four Population-based Breast Cancer Screening Programs in Spain. Radiology, 2011, 258, 388-395.	7.3	32
87	Risk factors for multidrug-resistant Pseudomonas aeruginosa acquisition. Impact of antibiotic use in a double case–control study. European Journal of Clinical Microbiology and Infectious Diseases, 2010, 29, 335-339.	2.9	46
88	Phenotypic characterization and risk factors for interval breast cancers in a population-based breast cancer screening program in Barcelona, Spain. Cancer Causes and Control, 2010, 21, 1155-1164.	1.8	58
89	Determination of biological variation of α-fetoprotein and choriogonadotropin (β chain) in disease-free patients with testicular cancer. Clinical Chemistry and Laboratory Medicine, 2010, 48, 1799-1801.	2.3	8
90	Implementation of Digital Mammography in a Population-based Breast Cancer Screening Program: Effect of Screening Round on Recall Rate and Cancer Detection. Radiology, 2009, 252, 31-39.	7.3	48

#	Article	IF	CITATIONS
91	Effectiveness and safety of colistin for the treatment of multidrug-resistant Pseudomonas aeruginosa infections. Infection, 2009, 37, 461-465.	4.7	87
92	Effect of participation on the cumulative risk of false-positive recall in a breast cancer screening programme. Public Health, 2009, 123, 635-637.	2.9	4
93	Trends in hormone therapy use before and after publication of the Women's Health Initiative trial. Menopause, 2009, 16, 1061-1064.	2.0	40
94	Results of a cervical cancer screening programme from an area of Barcelona (Spain) with a large immigrant population. European Journal of Public Health, 2009, 19, 499-503.	0.3	4
95	Seroprevalence of Bartonellaspp. infection in HIV patients in Catalonia, Spain. BMC Infectious Diseases, 2008, 8, 58.	2.9	26
96	Occupation and bladder cancer in a hospital-based case-control study in Spain. Occupational and Environmental Medicine, 2008, 65, 347-353.	2.8	64
97	Evaluation of hand hygiene adherence inÂa tertiary hospital. American Journal of Infection Control, 2007, 35, 676-683.	2.3	73
98	Association Between Visual Impairment and Patient-Reported Visual Disability at Different Stages of Cataract Surgery. Ophthalmic Epidemiology, 2006, 13, 299-307.	1.7	14
99	Smoking and Bladder Cancer in Spain: Effects of Tobacco Type, Timing, Environmental Tobacco Smoke, and Gender. Cancer Epidemiology Biomarkers and Prevention, 2006, 15, 1348-1354.	2.5	148
100	Cancer Mortality in Workers Exposed to Organochlorine Compounds in thePulp and Paper Industry: An International Collaborative Study. Environmental Health Perspectives, 2006, 114, 1007-1012.	6.0	29
101	Breastfeeding and concentrations of HCB and p,p′-DDE at the age of 1 year. Environmental Research, 2005, 98, 8-13.	7.5	48
102	Focus on hepatocellular carcinoma. Cancer Cell, 2004, 5, 215-219.	16.8	523
103	Gender-Related Differences in Clinical and Pathological Characteristics and Therapy of Bladder Cancer. European Urology, 2003, 43, 53-62.	1.9	47
104	Floods triggered by natural conditions and by human activities in a mediterranean coastal environment. Geografiska Annaler, Series A: Physical Geography, 2003, 85, 301-312.	1.5	19
105	Organochlorine compounds and concentrations of thyroid stimulating hormone in newborns. Occupational and Environmental Medicine, 2003, 60, 301-303.	2.8	52
106	Reference Change Value for α-Fetoprotein and Its Application in Early Detection of Hepatocellular Carcinoma in Patients with Hepatic Disease. Clinical Chemistry, 2003, 49, 1209-1211.	3.2	27
107	Social context for workplace health promotion: feasibility considerations in Costa Rica, Finland, Germany, Spain and Sweden. Health Promotion International, 2003, 18, 115-126.	1.8	23
108	Breastfeeding, Exposure to Organochlorine Compounds, and Neurodevelopment in Infants. Pediatrics, 2003, 111, e580-e585.	2.1	167

#	Article	IF	CITATIONS
109	Exposure to Asbestos and Lung and Pleural Cancer Mortality Among Pulp and Paper Industry Workers. Journal of Occupational and Environmental Medicine, 2002, 44, 579-584.	1.7	17
110	Assessment of Feasibility of Workplace Health Promotion. Preventive Medicine, 2002, 35, 232-240.	3.4	9
111	Serum organochlorines and urinary porphyrin pattern in a population highly exposed to hexachlorobenzene. Environmental Health, 2002, 1, 1.	4.0	27
112	Evaluation of urinary porphyrin excretion in neonates born to mothers exposed to airborne hexachlorobenzene Environmental Health Perspectives, 2002, 110, 205-209.	6.0	12
113	Health promotion trials at worksites and risk factors for cancer. Scandinavian Journal of Work, Environment and Health, 2002, 28, 141-157.	3.4	56
114	Association between serum concentrations of hexachlorobenzene and polychlorobiphenyls with thyroid hormone and liver enzymes in a sample of the general population. Occupational and Environmental Medicine, 2001, 58, 172-177.	2.8	89
115	Polychlorinated biphenyls (PCBs) and neurological development in children: a systematic review. Journal of Epidemiology and Community Health, 2001, 55, 537-546.	3.7	171
116	Coffee consumption and bladder cancer in nonsmokers: a pooled analysis of case-control studies in European countries. Cancer Causes and Control, 2000, 11, 925-931.	1.8	52
117	Serum concentrations of hexachlorobenzene in family members of workers in an electrochemical factory. Scandinavian Journal of Work, Environment and Health, 2000, 26, 67-70.	3.4	7
118	Organochlorine in the serum of inhabitants living near an electrochemical factory. Occupational and Environmental Medicine, 1999, 56, 152-158.	2.8	67
119	Health Effects of Chronic High Exposure to Hexachlorobenzene in a General Population Sample. Archives of Environmental Health, 1999, 54, 102-109.	0.4	46
120	Urinary Porphyrin Excretion in a Human Population Highly Exposed to Hexachlorobenzene. Archives of Dermatology, 1999, 135, 400-4.	1.4	20
121	Cancer risk in the rubber industry: a review of the recent epidemiological evidence. Occupational and Environmental Medicine, 1998, 55, 1-12.	2.8	142
122	A Death Certificate-Based Study of Occupation and Mortality From Reproductive Cancers Among Women in 24 US States. Journal of Occupational and Environmental Medicine, 1998, 40, 632-639.	1.7	19
123	Pesticides and congenital malformations - how many studies will it take to reach a conclusion?. Scandinavian Journal of Work, Environment and Health, 1998, 24, 445-447.	3.4	13
124	Metabolism of hexachlorobenzene in humans: association between serum levels and urinary metabolites in a highly exposed population Environmental Health Perspectives, 1997, 105, 78-83.	6.0	76
125	Risk excess of soft-tissue sarcoma and thyroid cancer in a community exposed to airborne organochlorinated compound mixtures with a high hexachlorobenzene content. International Journal of Cancer, 1994, 56, 200-203.	5.1	116
126	Effects of fire and of clearing in a Mediterranean Quercus ilex woodland: An experimental approach. Catena, 1992, 19, 321-332.	5.0	29

0

# AF	RTICLE	IF	CITATIONS
127 Cł ne	Changes in methylation pattern of albumin and $\hat{I}\pm$ -fetoprotein genes in developing rat liver and eoplasia. Nucleic Acids Research, 1983, 11, 4335-4354.	14.5	74

128 Mediterranean landscapes. , 0, , 297-320.